Literature DB >> 2046270

Hyperlipidemia and progressive renal disease.

W F Keane1, W S Mulcahy, B L Kasiske, Y Kim, M P O'Donnell.   

Abstract

Experimental studies have suggested an important role for abnormal lipid metabolism as an integral factor in modulating progressive renal damage. Dietary induced hypercholesterolemia induced relatively modest glomerular injury. However, in the presence of reduced nephron population or in the presence of underlying renal diseases, such as diabetes, nephrotic syndrome, and hypertension, nephron injury can be markedly exaggerated. These experimental results suggest that an important interaction may occur between renal disease and the occurrence of abnormalities of lipid metabolism. Additional support for the role of lipids in progressive renal injury can be obtained from studies in which pharmacological interventions reduced circulating lipids and this led to decreased glomerular damage. The mechanisms whereby lipids may amplify glomerular injury are not completely understood but may include an interaction with macrophages, alteration in vascular and mesangial functions, changes in production of mediator substances or alterations in membrane fluidity. Local glomerular modification of lipoproteins could also occur and contribute to the development of glomerular pathologic changes. Clinically, few data are available that provide insights into the potential role of renal-related lipid abnormalities in the progression of human renal disease.

Entities:  

Mesh:

Year:  1991        PMID: 2046270

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  11 in total

1.  Antibodies reactive to non-HLA antigens in transplant glomerulopathy.

Authors:  Rajani Dinavahi; Ajish George; Anne Tretin; Enver Akalin; Scott Ames; Jonathan S Bromberg; Graciela Deboccardo; Nicholas Dipaola; Susan M Lerner; Anita Mehrotra; Barbara T Murphy; Tibor Nadasdy; Estela Paz-Artal; Daniel R Salomon; Bernd Schröppel; Vinita Sehgal; Ravi Sachidanandam; Peter S Heeger
Journal:  J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 10.121

2.  Liposorber® LA-15 system for LDL apheresis in resistant nephrotic syndrome patients.

Authors:  Mohammad Al-Mousily; Oana Nicoara; David T Selewski; Katherine Twombley
Journal:  Pediatr Nephrol       Date:  2021-08-28       Impact factor: 3.714

3.  Prevalence of mild impairment in renal function in a random sample of elders from a biethnic community survey.

Authors:  R D Lindeman; L J Romero; C L Yau; R N Baumgartner; P J Garry
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 4.  Rosuvastatin in elderly patients.

Authors:  Michael H Davidson
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 5.  Lipid changes in the nephrotic syndrome: new insights into pathomechanisms and treatment.

Authors:  G D'Amico
Journal:  Klin Wochenschr       Date:  1991-09-03

6.  Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis.

Authors:  M Hattori; K Ito; H Kawaguchi; T Tanaka; R Kubota; M Khono
Journal:  Pediatr Nephrol       Date:  1993-04       Impact factor: 3.714

Review 7.  Focal segmental glomerulosclerosis.

Authors:  I Ichikawa; A Fogo
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

Review 8.  Disturbances of lipid metabolism in children with chronic renal failure.

Authors:  U Querfeld
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

9.  Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats.

Authors:  Qiu-yu Xu; Yin-hui Liu; Qi Zhang; Bo Ma; Zhen-dong Yang; Lei Liu; Di Yao; Guang-bo Cui; Jing-jing Sun; Zi-mei Wu
Journal:  Acta Pharmacol Sin       Date:  2014-09-15       Impact factor: 6.150

10.  Mechanisms of progression of chronic kidney disease.

Authors:  Agnes B Fogo
Journal:  Pediatr Nephrol       Date:  2007-07-24       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.